Resources

PATH is accelerating the development of pharmaceutical injection technologies aimed at improving access, adherence, and delivery of essential medicines in resource-constrained settings through product innovation. Long-acting pharmaceuticals often require parenteral delivery, are viscous, have large or non-standard dose volumes, may not be compatible with standard device materials, and are expensive to manufacture. Innovative delivery devices can help address critical diseases such as malaria, tuberculosis, hepatitis B and C, rabies, Ebola, and other neglected tropical diseases, as well as rising noncommunicable diseases such as cancer and diabetes. With that aim, PATH is identifying suitable packaging and delivery solutions that can reduce costs, improve access, and maximize impact of long-acting pharmaceuticals.

Women’s health and well-being are the cornerstone of family health, yet women remain chronically underserved, driven by fragmented health systems, misaligned policies, underinvestment in women‑centered research, and limited access to lifesaving services and products. Investing in women's and family health and the systems that serve them leads to transformative gains, leading to healthier communities, and economies.As a pillar of our approach to enhancing primary health care, PATH has been partnering with countries to advance health equity for women and families--applying a life-course driven approach and integrated people-centered care to increase access to high-quality products and services for women and their families that prioritize dignity, informed choice, and autonomy.This brief summarizes core tenets of PATH's approach to advancing integrated life-course care for women and their families and spotlights examples of our expertise across our maternal, newborn, and child health and sexual and reproductive health portfolio.

Malaria progress off trackAccording to the 2025 World Malaria Report, global progress in reducing malaria deaths is falling far short. In 2024, there were 610,000 deaths—more than 3 times the global target—and an estimated 282 million cases. The report highlights intensifying risks to malaria control, including antimalarial drug resistance, parasite gene deletions that undermine diagnostic tests, insecticide resistance that reduces the effectiveness of bed nets, and the invasive mosquito Anopheles stephensi, which poses a serious challenge to urban malaria control. Extreme weather events, shifting temperatures and rainfall, and conflict and instability are also driving outbreaks and disruptions to health services. Meanwhile, global funding for malaria has plateaued at less than half the target set by the Global Technical Strategy, with recent reductions in development assistance severely impacting interventions.PATH’s commitmentPATH is dedicated to reversing stalled progress and addressing these growing threats. Our 2026-2030 strategy prioritizes strong alignment and coordination within the global malaria ecosystem. Central to this strategy are seven core pillars, recognized globally as essential to driving transmission down to zero. These pillars align with the RBM Partnership Big Push Framework, the WHO Global Technical Strategy, and the 2024 Yaoundé Declaration for a Big Push against malaria endorsed by African Ministers of Health.Through coordinated action and strategic alignment, PATH aims to maximize resources and achieve the greatest impact in the fight against malaria.

Use these slide decks to share the evidence supporting a single-dose regimen of HPV vaccine. Visit the Single-Dose HPV Vaccine Evaluation Consortium page for additional resources.

High–quality evidence assessing single–dose HPV vaccination suggests that implementing a single–dose schedule is scientifically sound, and provides the greatest public health benefit.A single–dose HPV vaccination schedule has the potential to reach more girls and avert a greater number of cervical cancer cases than reaching fewer girls with a two–dose regimen.This brief provides a list of frequently asked questions and answers about the evidence around single–dose HPV vaccination, and the current policy landscape.